Thus, further studies are needed to clarify the clinical and pathological effects of IFN-α therapy in patients with PEComa and the risks of IFN therapy should be weighed against the potential benefits in any patient lacking detectable residual tumor. Here, IFNA1 is linked to neoplasm.